Esperion Therapeutis.Inc. buy Global_Player
Summary
This prediction ended on 27.04.24 with a price of €1.83. With a performance of -1.11%, the BUY prediction by Global_Player finished with a loss. Global_Player has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Esperion Therapeutis.Inc. | 1.770% | 1.770% | 62.257% |
| iShares Core DAX® | -1,66 % | -10,87 % | -0,72 % |
| iShares Nasdaq 100 | -3,77 % | -5,15 % | 13,41 % |
| iShares Nikkei 225® | -2,80 % | -11,30 % | 25,46 % |
| iShares S&P 500 | -2,30 % | -4,80 % | 8,94 % |
According to Global_Player what are the pros and cons of Esperion Therapeutis.Inc. for the foreseeable future?
Pros
Cons
Comments by Global_Player for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Stopped prediction by Global_Player for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
29.08.25
29.08.26
15.09.25
Esperion Therapeutis.Inc.
26.02.25
26.02.26
01.03.25
Esperion Therapeutis.Inc.
28.08.23
28.08.24
30.08.23
Esperion Therapeutis.Inc.
07.12.22
07.12.23
11.12.22
Esperion Therapeutis.Inc.
26.07.21
26.07.22
08.08.21


